Refractory Myelodysplastic/Myeloproliferative Neoplasm Clinical Trials in Rochester, Minnesota

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms